These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3987786)

  • 1. Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure.
    Ogata H; Kawatsu Y; Maruyama Y; Machida K; Haga T
    Eur J Clin Pharmacol; 1985; 28(1):53-9. PubMed ID: 3987786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotransformation of furosemide in kidney transplant patients.
    Smith DE; Benet LZ
    Eur J Clin Pharmacol; 1983; 24(6):787-90. PubMed ID: 6350024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and absolute bioavailability of furosemide in healthy males.
    Waller ES; Hamilton SF; Massarella JW; Sharanevych MA; Smith RV; Yakatan GJ; Doluisio JT
    J Pharm Sci; 1982 Oct; 71(10):1105-8. PubMed ID: 7143205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the fate of furosemide in man.
    Beermann B; Dalén E; Lindström B; Rosén A
    Eur J Clin Pharmacol; 1975 Oct; 9(1):51-61. PubMed ID: 1233253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diuretic effect and disposition of furosemide in cystic fibrosis.
    Prandota J; Smith IJ; Hilman BC; Wilson JT
    Eur J Clin Pharmacol; 1991; 40(4):333-41. PubMed ID: 2050167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.
    Lee MG; Chiou WL
    J Pharmacokinet Biopharm; 1983 Dec; 11(6):623-40. PubMed ID: 6678312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of two preparations of furosemide and their pharmacological activity in normal volunteers.
    Ogata H; Zugarni S; Ejima A; Kawatsu Y
    Eur J Clin Pharmacol; 1983; 24(6):791-6. PubMed ID: 6688397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure.
    Paterna S; Di Gaudio F; La Rocca V; Balistreri F; Greco M; Torres D; Lupo U; Rizzo G; di Pasquale P; Indelicato S; Cuttitta F; Butler J; Parrinello G
    Adv Ther; 2015 Oct; 32(10):971-82. PubMed ID: 26521190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics and dynamics of furosemide and slow-acting furosemide.
    Beermann B
    Clin Pharmacol Ther; 1982 Nov; 32(5):584-91. PubMed ID: 7127999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bumetanide and furosemide.
    Brater DC; Chennavasin P; Day B; Burdette A; Anderson S
    Clin Pharmacol Ther; 1983 Aug; 34(2):207-13. PubMed ID: 6872415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis.
    Hammarlund MM; Paalzow LK; Odlind B
    Eur J Clin Pharmacol; 1984; 26(2):197-207. PubMed ID: 6723758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cimetidine on the absorption and efficacy of orally administered furosemide.
    Rogers HJ; Morrison P; House FR; Bradbrook ID
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):8-11. PubMed ID: 7056605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variable furosemide absorption and poor predictability of response in elderly patients.
    Murray MD; Haag KM; Black PK; Hall SD; Brater DC
    Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor.
    Rakhit A; Kochak GM; Tipnis V; Hurley ME
    Clin Pharmacol Ther; 1987 May; 41(5):580-6. PubMed ID: 3032491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of intraindividual variability in bioavailability studies of furosemide.
    Grahnén A; Hammarlund M; Lundqvist T
    Eur J Clin Pharmacol; 1984; 27(5):595-602. PubMed ID: 6519165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure.
    Andreasen F; Mikkelsen E
    Eur J Clin Pharmacol; 1977 Aug; 12(1):15-22. PubMed ID: 902673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers.
    Lesne M
    Arzneimittelforschung; 1988 Jan; 38(1A):160-3. PubMed ID: 3370062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of furosemide in congestive heart failure.
    Nomura A; Yasuda H; Minami M; Akimoto T; Miyazaki K; Arita T
    Clin Pharmacol Ther; 1981 Aug; 30(2):177-82. PubMed ID: 7249502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of furosemide urinary elimination by nephrotic children.
    Prandota J
    Pediatr Res; 1983 Feb; 17(2):141-7. PubMed ID: 6828331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.